CEFTRIAXONE SODIUM FOR INJECTION BP POWDER FOR SOLUTION

País: Canadá

Língua: inglês

Origem: Health Canada

Ingredientes ativos:

CEFTRIAXONE (CEFTRIAXONE SODIUM)

Disponível em:

STERIMAX INC

Código ATC:

J01DD04

DCI (Denominação Comum Internacional):

CEFTRIAXONE

Dosagem:

500MG

Forma farmacêutica:

POWDER FOR SOLUTION

Composição:

CEFTRIAXONE (CEFTRIAXONE SODIUM) 500MG

Via de administração:

INTRAMUSCULAR

Unidades em pacote:

15ML

Tipo de prescrição:

Prescription

Área terapêutica:

THIRD GENERATION CEPHALOSPORINS

Resumo do produto:

Active ingredient group (AIG) number: 0117292005; AHFS:

Status de autorização:

APPROVED

Data de autorização:

2010-11-19

Características técnicas

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CEFTRIAXONE SODIUM FOR INJECTION BP
Sterile Powder for Solution, 250 mg, 500 mg, 1 g, 2 g and 10 g
ceftriaxone (as ceftriaxone
sodium) per vial,
Intravenous or Intramuscular
BP
Antibiotic
SteriMax Inc.
2770 Portland Drive,
Oakville, ON
L6H 6R4
Control No. 259108
Date of Initial Authorization:
November 19, 2010
Date of Revision:
July 6, 2022
Page 2 of 55
RECENT MAJOR LABEL CHANGES
1 INDICATIONS, 1.1 PEDIATRICS
12/2021
1 INDICATIONS, 1.2 GERIATRICS
12/2021
4 DOSAGE AND ADMINISTRATION, 4.1 DOSING CONSIDERATIONS
12/2021
4 DOSAGE AND ADMINISTRATION, 4.2 RECOMMENDED DOSE
AND DOSAGE ADJUSTMENT
12/2021
4 DOSAGE AND ADMINISTRATION, 4.3 RECONSTITUTION
12/2021
4 DOSAGE AND ADMINISTRATION, 4.4 ADMINISTRATION
12/2021
7 WARNINGS AND PRECAUTIONS, 7.1.1 PREGNANT WOMEN
12/2021
7 WARNINGS AND PRECAUTIONS, 7.1.2 BREAST-FEEDING
12/2021
7 WARNINGS AND PRECAUTIONS, 7.1.3 PEDIATRICS
12/2021
7 WARNINGS AND PRECAUTIONS, 7.1.4 GERIATRICS
12/2021
TABLE OF CONTENTS
SECTION OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.....................................................................................
2
TABLE OF CONTENTS
..........................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................
4
1
INDICATIONS..............................................................................................................
4
1.1
Pediatrics
...........................................................................................................
5
1.2
Geriatrics............................................................................................................
5
2
CONTRAINDICATIONS
...............................................................................................
5
4
DOSAGE AND ADMINISTRATION
.........................................................................